Key result
Long-term calcium antagonist therapy was evaluated in 84 patients with hypertrophic cardiomyopathy over a mean follow-up of 52 months, though specific efficacy results were not provided in the excerpt.
Why the study?
Does high-dose calcium antagonist therapy improve hemodynamics, symptoms, and survival in patients with hypertrophic cardiomyopathy?
Population
84 consecutive patients with confirmed hypertrophic cardiomyopathy, mean age 43 years, 20 female and 64 male.
Design
Cohort
Follow-up
mean 52 months
Authors
Loading...
Supports calcium antagonist use in HCM; leaves open randomized confirmation of benefits.
Observational (n=84)
No
Does high-dose calcium antagonist therapy improve hemodynamics, symptoms, and survival in patients with hypertrophic cardiomyopathy?
Long-term therapy with high-dose calcium antagonists in patients with hypertrophic cardiomyopathy improves hemodynamics, symptoms, and appears to reduce annual mortality.
Hopf et al. (1988) conducted an observational in Hypertrophic cardiomyopathy (n=84). Calcium antagonists (verapamil, gallopamil, nifedipine) was evaluated. Long-term calcium antagonist therapy was evaluated in 84 patients with hypertrophic cardiomyopathy over a mean follow-up of 52 months, though specific efficacy results were not provided in the excerpt.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: